

Claims

I claim:

1. A method for preventing or reducing the severity of autoimmune disease wherein said method comprises the administration of a prostaglandin inhibitor.

2. The method, according to claim 1, which comprises the administration of a compound that decreases the production, or blocks the activity, of PGS-2.

3. The method, according to claim 2, wherein said compound is indomethacin.

4. The method, according to claim 3, which further comprises the administration of aminoguanidine.

5. The method, according to claim 2, wherein said compound is NS-398.

6. The method, according to claim 1, which further comprises the administration of an antigen associated with said autoimmune disease.

7. The method, according to claim 1, wherein said disease is insulin-dependent diabetes.

8. The method, according to claim 6, wherein said antigen is selected from the group consisting of insulin, GAD, IA-2, and antigenic fragments and variants of these antigens.

9. A method for increasing the production of IL-1RA wherein said method comprises the administration of a PGS-2 inhibitor.

inhibiting
only indomethacin
PGS-2 inhibitor

IS this target

is IA-2
diabetes

appearing to be
an inhibitor
of IL-1RA
PGS-2
activity